The NES is an emerging disease in eating behavior that combines
eating disorders, sleep, mood and stress. In recent years, the NES is becoming more interested in close association with
obesity and depression. In the present study we have followed for 12 weeks 5 patients (2 males and 3 females) with NES and comorbid depression treated with
agomelatine (25 mg / day for the first two weeks, then 50 mg / day), an
antidepressant similar of
melatonin. At the end of the three months of treatment, it was found an improvement in symptoms characteristic of the NES, as assessed by a reduction an average of the NEQ (from 31 to 22.8), improved mood, mean values reduced by 23, 2 to 13.2 on the HAM-D,
weight reduction, an average of 3.6 kg reduction in average weekly awakenings from 12 to 6.4 and the time of
snoring and motion detected polysomnography. The serum chemistry values remained stable and there were no reported adverse events. The present study showed that the treatment with
agomelatine has improved the symptoms of NES and mood, decrease of
body weight, reduce, albeit not in an optimal manner, the number of awakenings per night with a reduction of movement time and
snoring . Of course, these preliminary data need to be confirmed by controlled trials on a larger sample.